Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN: BMN 333 versus vosoritide in children with achondroplasia
PACTR202608612874520Phase 2Not yet recruiting
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of BMN 333 and vosoritide in achondroplasia (ACH) (6 arms), sponsored by BioMarin Pharmaceutical Inc. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BMN 333vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on PACTR202608612874520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608612874520.